Here we assessed the effectiveness of cervical cancer screening using data from the Hiroshima Prefecture Cancer Registry regarding patient age at the start of screening and differences in screening intervals. A screening model was created to calculate the health status in relation to prognosis following cervical cancer screening and its influence on life expectancy. Epidemiological data on the mortality rate of cervical cancer by age groups and mortality rates from the Hiroshima Prefecture Cancer Registry were used for the model projections. Our results showed that life expectancy when screening rate was 100% compared with 0% was extended by approximately 1 month. Furthermore, when the incidence of cervical cancer was 0% compared with the screening rate was 100%, life expectancy was extended by a maximum of 3 months.
Introduction Introduction Introduction Introduction
In 2008, there were an estimated 530,000 new cervical cancer cases worldwide and about 270,000 deaths from the disease (The GLOBOCAN 2008 database -International Agency for Research on Cancer; http://www-dep.iarc.fr/; accessed on October 1, 2012).
According to the Japanese cancer information service (http://ganjoho.jp/public/cancer/data/cervix_uteri.html; accessed on October 1, 2012; in Japanese), as of 2006, roughly 9000 women per year developed cervical cancer in Japan, of which approximately 2700 died from the disease. In recent years, there has been an increasing trend in both the incidence and mortality rate of cervical cancer in younger women in their 20s and peaking in those in their 30s. Furthermore, it was reported that invasive cervical cancer in the 20-29 year age group had increased 4-fold from 1984 to 1996 (Urushigawa Kuni et al., 2001) and, 20 years from now, the number of cases is expected to increase by >1.5-fold. (Estimated cancer 5-year prevalence -Cancer Statistics 2007, p. 92-93, Cancer Research Foundation, Tokyo, Japan;  http://ganjoho.jp/data/public/statistics/backnumber/odjrh3000000o8is-att/FIG21.PDF; accessed on October 1, 2012). It is believed that the increased incidence in cervical cancer is due to women having their first sexual experience at a younger age.
The effectiveness of cervical cancer screening is widely recognized and while it is important to determine the rate of advanced cervical cancer cases, screening is also 4 important for early detection of the disease. However, the low rate of cervical cancer screening remains a crucial issue (Basic Plan to Promote Cancer Control). Although cervical cancer screening had been recommended annually, in 2004, the age to undergo an initial exam was lowered from 30 to 20 years and the interval between screenings was increased to 2 years. According to an international comparison of cancer mortality and screening rates, the rate of cervical cancer screening in Japan is extremely low compared with those in Europe and the USA (21% vs. 85%, respectively; International Comparisons of Cancer Mortality and Cancer Screening Rates; accessed on October 1, 2012), which is believed to be a significant factor contributing to the delay in early detection. According to reports on cervical cancer screening, the most common reason why women do not undergo the procedure is that they do not have the time or it is too much of a trouble (48.3%) (http://www.cczeropro.jp/kenshin/img/result/result.pdf#search = "report on cervical cancer screening"; accessed on October 1, 2012). Although patients are exposed to virtually no risks or physical pain incurred by the scraping of cells from the cervix in itself, the psychological stress is considered significant (Guidelines for making it the 12 th most common disease among women and the 15 th leading cause of death. However, neither the incidence nor the mortality rates included carcinoma in situ cases. If we consider the age-adjusted incidence rate of cervical cancer in 2007, it tended to decrease in women aged >40 years, but increased in those 20-39 years old, thereby demonstrating the importance of early detection. Thus, if the rate of cervical screening is increased, it would allow for improved detection and treatment of early stage cervical cancer and uterus preservation by local excision. In other words, early detection is crucial to preserve fertility in young women and reduce the mortality rate of cervical cancer and subsequent medical care expenses. Therefore, we created a cancer 6 screening model based on data from the Hiroshima Prefecture Cancer Registry and quantitatively evaluated the extent of mean life expectancy according to rate of cervical cancer screening. Values used in the screening model 
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For clinical cervical cancer staging, we used the Union for International Cancer Control
Tumor-Lymph node-Metastasis classification system and other cancer staging manuals developed by various academic societies and research institutions, while the local cancer registry was used to determine the extent of lesions modified into four stages: (1) localized; (2) regional lymph node metastasis; (3) invasion of adjacent organs; and (4) distal metastasis. In the model, "extent of lesion" was designated as a stage and the parameter value was estimated so that the likelihood was maximized from observed data using the maximum likelihood method. Cervical cancer screening reduces the incidence of invasive cancer by early detection and treatment of precancerous lesions and carcinomas in situ, and is expected to reduce the cervical cancer mortality rate.
However, when suitable treatment is administered, even in cases with precancerous lesions or carcinoma in situ, the tumor control rate of carcinoma in situ (stage 0) is 9 reportedly almost 100% (Quinn MA et al.,2006) . In other words, there was not much difference between healthy individuals and the death rate. Moreover, it is rare to progress to advanced stage cancer; thus, we excluded carcinoma in situ from the screening model. Numerical values of the incidence and mortality rates of cervical cancer according to different age groups were obtained from the Hiroshima Prefecture Cancer Registry (2005) (2006) (2007) . For the overall mortality rate, we included the mortality rates of other diseases as analytical parameters obtained from the Abridged Life Table of National Health Trends (2010) (2011) . Screening age was assumed as 20-65 years, 30-65 years, and 40-65 years. Intervals between screenings were defined from 1 to 5 years.
Other parameters
According to data obtained from reports on community health services and promotion, the cervical cancer screening rate was 20%. Regression analysis was performed to determine a coefficient for the excess mortality rate of cervical cancer from the survival curve of the 5-year survival rate. The age at start of follow-up was set at 20 years to 10 study the effect of screening. cases/100,000 women, thereby confirming the validity of the model (Figure 2-1 ).
Evaluati
Furthermore, we confirmed the estimated mortality rate calculated using the model as 6.9 deaths/100,000 women (Figure 2-2) . The age at the start of cervical cancer screening and the interval between screenings of the 100,000 virtual cohort members were adjusted to compare the efficacy of screening (screening rate, 100%). When the age at the start of screening (screening interval, 1
year; screening rate, 100%) was 20 years, the screening efficacy was approximately 34%, at 30 years, it was 32%, and at 40 years, approximately 24% (Figure 3 , Table 2 ).
Mean life expectancy of cervical patients
Figure4.
As mentioned above, the theoretical maximum value of mass screening was 0.21 years; therefore, we calculated the difference in life expectancy between the screened group and the non-screened group among cervical cancer patients. For instance, if an individual developed cervical cancer by age of 20, then there was a difference in mean life expectancy of approximately 13 years between the screened and non-screened groups (Figure 4 ).
Discussion
Discussion Discussion Discussion
We examined the extent of changes in mean life expectancy according to changes in the rate of cervical cancer screening using a mathematical screening model. As a general rule, in Japan, women aged ≥30 years underwent annual screenings from 1983 to 2002.
According to earlier studies and systems implemented in other nations (Sawaya GF et al., 2003; Sasieni P et al., 2003) The screening model also indicated that there was virtually no difference in the incidence of cervical cancer among women who began screening at 20 or 30 years of age, although there were more cervical cancer-free women among those who started screening at 20 years of age.
Although the present screening model did not factor in carcinoma in situ, the incidence Usually, cervical cancer screening is performed annually; however, in 2003, it was recommended for alternate years. In our screening model, a shorter interval between screenings increased the mean life expectancy. However, biennial screenings may be 16 problematic because women who consider screening may be unsure of the relevant year and thus may not undergo screening. Results of a case-control study conducted in Japan revealed that between individuals screened annually and biennially, there was a significant decrease in the rate of early detection in those who underwent biennial screenings (Morimura Y and Ito M, 2005) . Moreover, a 2-year prevention may be anticipated from a negative biennial cytodiagnostic result; thus, annual screenings are likely much more effective (Sato S et al., 1997; Makino H et al., 1995) . Therefore, an investigation into restoring annual screening is warranted.
Recent analyses on cervical cancer have revealed the natural history of invasive cancer resulting from high-risk HPV infection of the cervical mucous membrane and the development of cervical carcinoma in situ or precancerous lesions (Cervical Cancer Screening Guidelines Based on Effective Evaluation,2009). In brief, there are approximately 150 types of HPV strains, of which 16 are high-risk (Miura S et al., 2006) , and >90% of HPV infections are eliminated naturally, although persistent infections can lead to cancer. After the discovery of high-risk HPV infection, an HPV vaccine was developed to prevent the onset of cervical cancer and today it is administered extensively throughout the world. A cost-effectiveness analysis on the introduction of the HPV vaccine indicated that it may contribute to a decrease in cervical cancer mortality among young women, but was not effective in women aged ≥40 years; therefore, screenings should be continued (Coupé VM ,et al ., 2009) . Moreover, there is concern regarding the effect of HPV vaccination on cervical cancer screening. Although the HPV vaccine has been directly linked to cervical cancer prevention in young women, those already infected by the HPV virus realize no benefits from the vaccination.
Furthermore, although the HPV vaccine prevents cervical cancer in 70% of cases (Muñoz N, et al .,2004 ; A National Clinical Guideline.2008) , the remaining 30% of cervical cancer cases are not prevented. Therefore, as in the past, cervical cancer screening should be provided for women aged ≥30 years.
The introduction of the HPV vaccine may greatly change the way cervical cancer screenings are performed in the future; however, since adolescents are the primary target for vaccine administration and there is no data regarding the duration HPV vaccine effectiveness, it is expected that preventive measures by cancer screening and vaccination will continue to coexist into the near future. HPV vaccine was not taken into account in this study, but screening procedures and preventive vaccines do exist for Nonetheless, early detection of cervical cancer allows for the preservation of the uterus and fertility. Moreover, the survival rate after treatment differs according to the tumor size and degree of invasion of cervical cancer when detected early. Therefore, early detection is crucial. As the rate of cervical screening increases, the incidence of cervical cancer will approach 0%. The cervical screening rate in Hiroshima Prefecture is below the national average and should, therefore, be increased.
Epidemiological data used in this study was collected from the Hiroshima Prefecture Cancer Registry, a notification-based clinical registry, and, at present, the data can be expected to be highly accurate even at an international level, as epidemiological studies using this data have been shown to yield highly reliable results. Although cancer 19 registration is not mandatory in Japan, the nation is moving to make it so by the end of 2013. Thus, if cancer registration becomes mandatory, we can expect highly accurate cancer registries to be established throughout Japan, which will allow us to ascertain trends that could not be estimated from regional data, clarify particularities of rare cancers, and analyze regional differences and survival rates. In the future, more data will be added to the registry thereby allowing further analyses.
Conclusion Conclusion Conclusion Conclusion
We developed a cervical cancer screening model based on data from the Hiroshima Prefecture Cancer Registry. Here we examined the effect of mass cervical cancer screening on mean life expectancy, which, at most, increased by 1 month. The age at the start of cervical cancer screening and the interval between screenings of the 100,000 virtual cohort members were adjusted to compare the efficacy of screening (screening rate, 100%). 
